Approximately 130–150 million people globally have a chronic hepatitis C infection, with 3 to 4 million new infections occurring each year.1
Antiviral medicines can cure approximately 90% of hepatitis C infections, thereby reducing the risk of death from liver cancer and cirrhosis. Access to diagnosis and treatment, however, is limited.
Roche Molecular introduced the first ever test to monitor HCV viral load in a person’s blood in 1993 and remains committed to helping eradicate the virus today.
Roche Molecular offers both qualitative and quantitative tests that allow clinicians and laboratories to detect HCV viral RNA, differentiate genotypes, and quantify viral load to assist in managing appropriate course of treatment for infected patients
- World Health Organization (WHO). Fact sheet No. 164: Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed May 13, 2016.